{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:22:32Z","timestamp":1760782952994},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":2045,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:p>Selegiline transdermal system is a recently approved monoamine oxidase inhibitor antidepressant. Medications that inhibit monoamine oxidase type A can augment the pressor effects of sympathomimetic amines, increasing the potential for hypertensive crisis. This study examined the potential for drug\u2010drug interactions during treatment with selegiline transdermal system and pseudoephedrine or phenylpropanolamine. Two studies were conducted with 25 healthy volunteers to assess changes in blood pressure and heart rate during administration of pseudoephedrine or phenylpropanolamine alone or together with selegiline transdermal system. No significant differences in mean maximum changes in vital signs occurred with pseudoephedrine. No significant differences were found in mean maximum changes in systolic heart rate with phenylpropanolamine; however, 4 of 12 subjects each experienced 1 isolated protocol\u2010defined minimal pressor response without concurrent adverse effects (1 with phenylpropanolamine alone; 3 with phenylpropanolamine + selegiline transdermal system). Pharmacokinetic parameters obtained following selegiline transdermal system and pseudoephedrine or phenylpropanolamine were unremarkable. The results suggest that selegiline transdermal system 6 mg\/24 h does not significantly alter the pharmacodynamics or pharmacokinetics of either pseudoephedrine or phenylpropanolamine when administered to healthy volunteers; however, it is prudent to avoid coadministration of selegiline transdermal system and sympathomimetics.<\/jats:p>","DOI":"10.1177\/0091270007302950","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T01:04:46Z","timestamp":1181178286000},"page":"978-990","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of the Potential for Pharmacodynamic and Pharmacokinetic Drug Interactions Between Selegiline Transdermal System and Two Sympathomimetic Agents (Pseudoephedrine and Phenylpropanolamine) in Healthy Volunteers"],"prefix":"10.1002","volume":"47","author":[{"given":"Albert J.","family":"Azzaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad M.","family":"VanDenBerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ziemniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence F.","family":"Blob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan J.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"124","article-title":"Monoamine oxidase inhibitors: a new generation","volume":"36","author":"Robinson DS","year":"2002","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199005030-00004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198912000-00002"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/emj.17.2.143"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/emj.12.1.49"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(82)80067-X"},{"key":"e_1_2_6_8_2","first-page":"64","article-title":"MAOIs and hypertensive crises: the role of OTC drugs","volume":"50","author":"Harrison WM","year":"1989","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C175"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199102000-00009"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90479-Y"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1838(96)00084-7"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000092917.96558.3C"},{"key":"e_1_2_6_14_2","first-page":"237","volume-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","author":"Westfall TC","year":"2006"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199614040-00002"},{"key":"e_1_2_6_16_2","first-page":"1","volume-title":"Burger's Medicinal Chemistry and Drug Discovery. Vol 6: Nervous system agents","author":"Griffith RK","year":"2003"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb01061.x"},{"issue":"4","key":"e_1_2_6_18_2","first-page":"S38","article-title":"MAO\u2010B inhibitors for the treatment of Parkinson's disease","volume":"17","author":"Goetz CG","year":"2002","journal-title":"Mov Disord"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199819010-00002"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01892-9"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2003.tb02430.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.11.1869"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0216"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000239794.37073.70"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006289852"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432501"},{"key":"e_1_2_6_27_2","volume-title":"Guidance for Industry: Bioavailability and Bioequivalence Studies on Orally Administered Drug Products\u2014General Considerations","year":"2003"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296151"},{"key":"e_1_2_6_29_2","volume-title":"Steady\u2010state pharmacokinetic comparison of the 10 mg and 20 mg selegiline transdermal system in healthy male volunteers","author":"Somerset Data on File: Study S9303\u2010P9923."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270007302950","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270007302950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T21:00:27Z","timestamp":1697144427000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270007302950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1177\/0091270007302950"],"URL":"https:\/\/doi.org\/10.1177\/0091270007302950","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}